{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036647","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.456923+00:00","generated_at":"2026-05-29T09:17:58.351900+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio","bullets":["Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.","Company cites positive Phase 2b SEISMiC study in early cardiogenic shock as catalyst for potential non-dilutive partnership.","Existing Lee's Pharmaceuticals deal offers up to $138M in milestones plus low double-digit royalties for Greater China.","NGA has advised on transactions with aggregate value approaching $400M from 2023 through 2024.","Proceeds from any deal would support advancement of Windtree's novel preclinical oncology platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036647","json":"https://secwatch.observer/filing/0001437749-24-036647.json","markdown":"https://secwatch.observer/filing/0001437749-24-036647.md","text":"https://secwatch.observer/filing/0001437749-24-036647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/0001437749-24-036647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/wint20241202_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:17:58.351900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}